Drug Profile
NN 1406
Alternative Names: NN1406; NNC0143-0406; NNC0143-0406 A; PI 406Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Unknown (SC, Injection)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Austria (SC, Injection)
- 04 Jul 2017 Novo Nordisk completes a phase I trial for Type-1 diabetes mellitus in Austria (NCT02938572)